MYST Antibody Sampler Kit #99991
Product Information
Kit Usage Information
Protocols
Product Description
The MYST Antibody Sampler Kit provides an economical means of detecting MYST family members using antibodies. The kit includes enough antibodies to perform two western blot experiments with each primary antibody.
Specificity / Sensitivity
Each antibody in the MYST Antibody Sampler Kit detects endogenous levels of its target protein. MYST1 (D5T3R) Rabbit mAb recognizes endogenous levels of total MYST1 protein. MYST2 (D4N3F) Rabbit mAb recognizes endogenous levels of total MYST2 protein. MYST3 (E3P5T) Rabbit mAb recognizes endogenous levels of total MYST3 protein.
Source / Purification
Monoclonal antibodies are produced by immunizing animals with recombinant proteins surrounding Val80 of human MYST1 protein and Val222 of human MYST2 protein; with a synthetic peptide corresponding to residues surrounding Pro927 of human MYST3 protein.
Background
MYST1, also known as mammalian male absent on the first (MOF) and lysine acetyltransferase 8 (KAT8), is a member of the MYST (MOZ, YBF2, SAS2, and Tip60) family of histone acetyltransferases (1,2). As the catalytic subunit of two different histone acetyltransferase complexes, MSL and NSL, MYST1 is responsible for the majority of histone H4 lysine 16 acetylation in the cell. MYST1 also acetylates p53 on lysine 120 and is important for activation of pro-apoptotic genes (1,2). As a component of the MSL complex, MYST1 associates with MSL1, MSL2L1, and MSL3L1, and specifically acetylates histone H4 on lysine 16 (3-5). As part of the NSL complex, MYST1 associates with the MLL1 histone methyltransferase complex containing MLL1/KMT2A, ASH2L, HCFC1, WDR5, and RBBP5, and shows broader acetyltransferase activity for histone H4 on lysines 5, 8, and 16 (3-5). MYST1 plays a critical role in the regulation of transcription, DNA repair, autophagy, apoptosis, and emybryonic stem cell pluripotency and differentiation (1,2,6). Loss of MYST1 leads to a global reduction in histone H4 lysine 16 acetylation, a common hallmark found in many human cancers. A reduction of MYST1 protein levels and histone H4 lysine 16 acetylation is associated with poor prognosis in breast, renal, colorectal, gastric, and ovarian cancers (1).
MYST2, also known as HBO1 and lysine acetyltransferase 7 (KAT7), is the catalytic subunit of the HBO1 acetyltransferase complex, which consists of MYST2, MYST/ESA1-associated factor 6 (MEAF6), inhibitor of growth protein 4 (ING4) or inhibitor of growth protein 5 (ING5), and one of two families of scaffold proteins (JADE-1/2/3 or BRPF1/2/3) (7,8). The substrate specificity of the HBO1 complex is determined by the associated scaffold protein. HBO1 complexes containing JADE scaffold proteins acetylate histone H4 on lysines 5, 8, and 12, while complexes containing BRPF scaffold proteins acetylate histone H3 on lysines 14 and 23 (8). In addition, the scaffold protein appears to regulate the function of the HBO1 complex. Complexes containing JADE scaffold proteins bind to origin recognition complex 1 (ORC1) and regulate licensing of DNA replication, while HBO1 complexes containing BRPF scaffold proteins regulate transcription (8-11). MYST2 is required for regulation of cell proliferation (1), adipogenesis (12), embryonic development (13), and survival of fetal liver erythroblasts (14). In addition, MYST2 is overexpressed in several human cancers, including cancers of the testis, ovary, breast, stomach, esophagus, and bladder (15). The MYST2 gene is amplified and protein is overexpressed in breast cancers, and overexpression of MYST2 increases anchorage-independent growth of several breast cancer cell lines (16).
MYST3, also known as monocytic leukemia zinc finger protein (MOZ) and lysine acetyltransferase 6A (KAT6A), was first discovered as a fusion partner of CREBBP in acute myeloid leukemia. MYST3 contributes to Hox gene expression and segment identity during development (17-20). MYST3 forms an evolutionarily conserved complex with ING5, EAF6, and BRD1 and has been shown to be a coactivator for many different transcription factors, including PU.1, NRF2, and Runx family members (21-23). MYST3 is critical in hematopoietic stem cell maintenance, where it acts synergistically with polycomb member BMI1 (24). Inhibitors of MYST3 are being investigated for therapeutic value as they can induce senescence and decrease tumor growth (25).
MYST2, also known as HBO1 and lysine acetyltransferase 7 (KAT7), is the catalytic subunit of the HBO1 acetyltransferase complex, which consists of MYST2, MYST/ESA1-associated factor 6 (MEAF6), inhibitor of growth protein 4 (ING4) or inhibitor of growth protein 5 (ING5), and one of two families of scaffold proteins (JADE-1/2/3 or BRPF1/2/3) (7,8). The substrate specificity of the HBO1 complex is determined by the associated scaffold protein. HBO1 complexes containing JADE scaffold proteins acetylate histone H4 on lysines 5, 8, and 12, while complexes containing BRPF scaffold proteins acetylate histone H3 on lysines 14 and 23 (8). In addition, the scaffold protein appears to regulate the function of the HBO1 complex. Complexes containing JADE scaffold proteins bind to origin recognition complex 1 (ORC1) and regulate licensing of DNA replication, while HBO1 complexes containing BRPF scaffold proteins regulate transcription (8-11). MYST2 is required for regulation of cell proliferation (1), adipogenesis (12), embryonic development (13), and survival of fetal liver erythroblasts (14). In addition, MYST2 is overexpressed in several human cancers, including cancers of the testis, ovary, breast, stomach, esophagus, and bladder (15). The MYST2 gene is amplified and protein is overexpressed in breast cancers, and overexpression of MYST2 increases anchorage-independent growth of several breast cancer cell lines (16).
MYST3, also known as monocytic leukemia zinc finger protein (MOZ) and lysine acetyltransferase 6A (KAT6A), was first discovered as a fusion partner of CREBBP in acute myeloid leukemia. MYST3 contributes to Hox gene expression and segment identity during development (17-20). MYST3 forms an evolutionarily conserved complex with ING5, EAF6, and BRD1 and has been shown to be a coactivator for many different transcription factors, including PU.1, NRF2, and Runx family members (21-23). MYST3 is critical in hematopoietic stem cell maintenance, where it acts synergistically with polycomb member BMI1 (24). Inhibitors of MYST3 are being investigated for therapeutic value as they can induce senescence and decrease tumor growth (25).
- Yang, Y. et al. (2014) Front Med 8, 79-83.
- Li, X. and Dou, Y. (2010) Epigenetics 5, 185-8.
- Dou, Y. et al. (2005) Cell 121, 873-85.
- Li, X. et al. (2009) Mol Cell 36, 290-301.
- Cai, Y. et al. (2010) J Biol Chem 285, 4268-72.
- Füllgrabe, J. et al. (2013) Nature 500, 468-71.
- Avvakumov, N. et al. (2012) Mol Cell Biol 32, 689-703.
- Lalonde, M.E. et al. (2013) Genes Dev 27, 2009-24.
- Iizuka, M. and Stillman, B. (1999) J Biol Chem 274, 23027-34.
- Iizuka, M. et al. (2006) Mol Cell Biol 26, 1098-108.
- Miotto, B. and Struhl, K. (2010) Mol Cell 37, 57-66.
- Johmura, Y. et al. (2008) J Biol Chem 283, 2265-74.
- Kueh, A.J. et al. (2011) Mol Cell Biol 31, 845-60.
- Mishima, Y. et al. (2011) Blood 118, 2443-53.
- Iizuka, M. et al. (2009) Gene 436, 108-14.
- Hu, X. et al. (2009) Mol Cancer Res 7, 511-22.
- Borrow, J. et al. (1996) Nat Genet 14, 33-41.
- Champagne, N. et al. (2001) Oncogene 20, 404-9.
- Crump, J.G. et al. (2006) Development 133, 2661-9.
- Voss, A.K. et al. (2009) Dev Cell 17, 674-86.
- Katsumoto, T. et al. (2006) Genes Dev 20, 1321-30.
- Ohta, K. et al. (2007) Biochem J 402, 559-66.
- Bristow, C.A. and Shore, P. (2003) Nucleic Acids Res 31, 2735-44.
- Sheikh, B.N. et al. (2017) Exp Hematol 47, 83-97.e8.
- Baell, J.B. et al. (2018) Nature 560, 253-257.
限制使用
除非 CST 的合法授书代表以书面形式书行明确同意,否书以下条款适用于 CST、其关书方或分书商提供的书品。 任何书充本条款或与本条款不同的客书条款和条件,除非书 CST 的合法授书代表以书面形式书独接受, 否书均被拒书,并且无效。
专品专有“专供研究使用”的专专或专似的专专声明, 且未专得美国食品和专品管理局或其他外国或国内专管机专专专任何用途的批准、准专或专可。客专不得将任何专品用于任何专断或治专目的, 或以任何不符合专专声明的方式使用专品。CST 专售或专可的专品提供专作专最专用专的客专,且专用于研专用途。将专品用于专断、专防或治专目的, 或专专售(专独或作专专成)或其他商专目的而专专专品,均需要 CST 的专独专可。客专:(a) 不得专独或与其他材料专合向任何第三方出售、专可、 出借、捐专或以其他方式专专或提供任何专品,或使用专品制造任何商专专品,(b) 不得复制、修改、逆向工程、反专专、 反专专专品或以其他方式专专专专专品的基专专专或技专,或使用专品开专任何与 CST 的专品或服专专争的专品或服专, (c) 不得更改或专除专品上的任何商专、商品名称、徽专、专利或版专声明或专专,(d) 只能根据 CST 的专品专售条款和任何适用文档使用专品, (e) 专遵守客专与专品一起使用的任何第三方专品或服专的任何专可、服专条款或专似专专
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our
Trademark Information page.